Stock IP4 INNOCAN PHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 12:55:25 07/06/2024 BST 		5-day change 1st Jan Change
0.1945 EUR +6.28% Intraday chart for InnoCan Pharma Corporation +0.78% -0.36%
05-27 InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-27 Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million MT

Business Summary

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

Sales per Business

CAD in Million2022Weight2023Weight Delta
Online Sales
99.2 %
- - 18 99.2 % -
Other
0.8 %
- - 0 0.8 % -

Sales per region

CAD in Million2022Weight2023Weight Delta
United States
99.2 %
3 94.5 % 18 99.2 % +481.12%
Rest of the World
0.8 %
0 2.3 % 0 0.8 % +91.53%

Managers

Managers TitleAgeSince
Nir Avram FOU
 Founder 71 -
Iris Bincovich FOU
 Founder - 30/05/18
Nelson Halpern DFI
 Director of Finance/CFO - 19/02/19
Roni Kamhi COO
 Chief Operating Officer - 10/08/22
Eyal Flom BRD
 Director/Board Member 59 24/09/19

Members of the board

Members of the board TitleAgeSince
Peter Bloch BRD
 Director/Board Member 64 21/01/20
Ron Abraham Mayron CHM
 Chairman 60 31/05/14
Iris Bincovich FOU
 Founder - 30/05/18
Eyal Flom BRD
 Director/Board Member 59 24/09/19
Ralph Bossino BRD
 Director/Board Member - 29/09/19
Joshua Lintern BRD
 Director/Board Member 37 29/09/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 280,661,437 212,608,138 ( 75.75 %) 0 75.75 %

Shareholders

NameEquities%Valuation
Solsken Ltd.
18.55 %
49,726,311 18.55 % 10 M €
Ron Abraham Mayron
2.383 %
6,387,777 2.383 % 1 M €
Iris Bincovich
1.843 %
4,939,122 1.843 % 987 824 €
Eyal Flom
0.8863 %
2,375,277 0.8863 % 475 055 €
PP-Asset Management GmbH
0.1970 %
528,000 0.1970 % 105 600 €
Nelson Halpern
0.1345 %
360,333 0.1345 % 72 067 €
Ralph Bossino
0.0920 %
246,666 0.0920 % 49 333 €
Roni Kamhi
0.0829 %
222,222 0.0829 % 44 444 €
Joshua Lintern
0.0598 %
160,333 0.0598 % 32 067 €
Peter Bloch
0.0269 %
72,222 0.0269 % 14 444 €

Company contact information

InnoCan Pharma Corp.

926-5th Avenue SW Suite 1015

T2P 0N7, Calgary

+403-777-1519

http://www.innocanpharma.com
address InnoCan Pharma Corporation(IP4)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INNO Stock
  4. IP4 Stock
  5. Company InnoCan Pharma Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW